News - OBI Pharma

2025.Dec.18

Corporate

OBI Investors’ Meeting Highlights Value Transformation Driven by ADC Innovation

2025.Dec.09

Corporate

OBI Pharma Presents Preclinical Results for Bispecific ADC OBI-201 at SABCS 2025

2025.Dec.05

Corporate

OBI-902 Receives Consecutive FDA Orphan Drug Designation
Indication Expanded to Gastric Cancer Including Gastroesophageal Junction Adenocarcinoma

2025.Nov.16

Corporate

OBI-902 has been granted by US FDA for Orphan Drug Designation for the treatment of Cholangiocarcinoma.

2025.Oct.21

Sustainability

OBI Volunteers Actively Participated in TBCA’s Pink October Event to Support Breast Cancer Awareness and Prevention

2025.Oct.08

Award & Certification

OBI Chairman Dr. Kung-Yee Liang Receives the 2024–2025 Presidential Science Prize

2025.Sep.26

Corporate

OBI Invited to Present ADC Technology Platform and Chaired Sessions at Biologics World Korea 2025

2025.Sep.03

Corporate

OBI Pharma and AP Biosciences Sign Technology Collaboration Agreement to Develop Next-Generation ADC

2025.Sep.01

Corporate

OBI Pharma, Inc. Announces Board Resolution for Capital Reduction to Offset Accumulated Losses and Holds Material Information Press Conference

2025.Aug.31

Corporate

OBI Pharma Announces Phase 1/2 Study Initiation for OBI-902, a TROP2 Targeted Antibody-Drug Conjugate Therapy (ADC) in Advanced Solid Tumors

Announcements

Latest announcements

Events

Latest events